Therapeutic cannabis extracts

Abstract

The present invention may be one of several formulations containing cannabinoids and non-cannabinoid compounds. Cannabis plants are subjected to extraction, and the resulting extract may be supplemented with additional ingredients to achieve a desired chemical profile. Dose titration may be used to find an appropriate dose of cannabis extract to be ingested in treating medical conditions.

What is claimed is: 
     
         1 . A therapeutic formulation comprising a cannabis extract wherein a weight of remainder equal to at least 10% to 40% by weight of total measured cannabinoids is added. 
     
     
         2 . A therapeutic formulation comprising 70% to 95% by weight of total measured cannabinoids, wherein a weight of remainder is added to the total cannabinoid weight to bring total weight up to 100% by weight. 
     
     
         3 . A therapeutic formulation comprising about 20% CBD by weight, about 60% Δ8-THC by weight and about less than about 5% by weight of other cannabinoids, where the listed percentages are weight percentage. 
     
     
         4 . The therapeutic formulation of  claim 3  further comprising at least 15% remainder by weight. 
     
     
         5 . The therapeutic formulation of  claim 3  further comprising 1-4% by weight added terpenoid compounds. 
     
     
         6 . The therapeutic formulation of  claim 5 , wherein the added terpenoid compounds consist essentially of about 0.05%-1% linalool by weight, about 0.05%-1% α-pinene by weight and about 0.05%-1% β-myrcene by weight. 
     
     
         7 . A therapeutic formulation comprising about 24% THCA by weight, about 48% CBDA by weight 
     
     
         8 . The therapeutic formulation of  claim 7  and at least 20% remainder by weight. 
     
     
         9 . The therapeutic formulation of  claim 7  further comprising about 2% THC by weight, about 1% CBD by weight, about 3% CBN by weight, about 4% Δ8-THC by weight, about 3% CBG by weight and about 1-3% THCV by weight. 
     
     
         10 . The therapeutic formulation of  claim 9  further comprising about 1-4% by weight added terpenoid compounds. 
     
     
         11 . The therapeutic formulation of  claim 10 , wherein the added terpenoid compounds consist essentially of about 0.05%-1% linalool by weight, about 0.05%-1% α-pinene by weight and about 0.05%-1% β-myrcene by weight. 
     
     
         12 . A therapeutic formulation comprising about 24% THC by weight and about 48% CBD by weight. 
     
     
         13 . The therapeutic formulation of  claim 12  further comprising at least 20% by weight remainder. 
     
     
         14 . The therapeutic formulation of  claim 12  further comprising about 2% THCA by weight, about 1% CBDA by weight, about 3% CBN by weight, about 3% CBG by weight and about 1-3% THCV by weight. 
     
     
         15 . The therapeutic formulation of  claim 12  further comprising about 1-4% by weight added terpenoid compounds. 
     
     
         16 . The therapeutic formulation of  claim 15 , wherein the added terpenoid compounds consist essentially of about 0.05%-1% linalool by weight, about 0.05%-1% α-pinene by weight and about 0.05%-1% β-myrcene by weight. 
     
     
         17 . The therapeutic formulation of  claim 12  further comprising about 0.05%-3% black pepper extract by volume. 
     
     
         18 . The therapeutic formulation of  claim 14  further comprising about 0.05-3% cassia cinnamon oil by volume. 
     
     
         19 . The therapeutic formulation of  claim 14  further comprising about 0.05-3% Ceylon cinnamon bark oil by volume. 
     
     
         20 . A therapeutic formulation comprising about 10% THCA and about 60% CBD. 
     
     
         21 . The therapeutic formulation of  claim 20  further comprising at least 20% by weight remainder. 
     
     
         22 . The therapeutic formulation of  claim 20  further comprising about 3% THC by weight, about 1% CBDA by weight, about 3% CBN by weight, about 1% Δ8-THC by weight, about 4% CBG by weight and about 1-3% THCV by weight. 
     
     
         23 . The therapeutic formulation of  claim 22  about 1-4% by weight added terpenoid compounds of 1-4% by weight 
     
     
         24 . The therapeutic formulation of  claim 23 , wherein the added terpenoid compounds consist essentially of about 0.05%-1% linalool by weight, about 0.05%-1% α-pinene by weight and about 0.05%-1% β-myrcene by weight. 
     
     
         25 . A therapeutic formulation comprising:
 a cannabinoid component selected to provide less than 0.3% THC by weight
 and less than 0.3% THCA by weight, about 65-75% CBD by weight, 
 and about 5-15% CBN by weight; 
   at least 10% by weight remainder; and   about 1-4% by weight added terpenoid compounds.   
     
     
         26 . The therapeutic formulation of  claim 25 , wherein the added terpenoid compounds consist essentially of about 0.05%-1% linalool by weight, about 0.05%-1% α-pinene by weight and about 0.05%-1% β-myrcene by weight. 
     
     
         27 . A therapeutic formulation comprising:
 a cannabinoid component selected to provide about 35% THC by weight,
 about 35% CBD by weight, about 3% CBN by weight, about 3% Δ8-THC by weight, and about 4% CBG by weight; 
   at least 15% by weight remainder; and   about 1-4% by weight added terpenoid compounds.   
     
     
         28 . The therapeutic formulation of  claim 27 , wherein the added terpenoid compounds consist essentially of about 0.05%-1% linalool by weight, about 0.05%-1% α-pinene by weight and about 0.05%-1% β-myrcene by weight. 
     
     
         29 . A therapeutic formulation comprising:
 a cannabinoid component selected to provide about 35% THC by weight,
 about 35% CBD by weight, about 3% CBN by weight, about 3% Δ8-THC by weight, and about 4% THCV by weight; 
   at least 15% by weight remainder; and   about 1-4% by weight added terpenoid compounds.   
     
     
         30 . The therapeutic formulation of  claim 29  wherein the added terpenoid compounds consist essentially of about 0.05%-1% linalool by weight, about 0.05%-1% α-pinene by weight and about 0.05%-1% β-myrcene by weight. 
     
     
         31 . A therapeutic formulation comprising a cannabinoid component selected to provide about equal amounts by THC and CBD and less than 5% by weight each of CBN, THC, and CBG. 
     
     
         32 . The therapeutic formulation of  claim 31  wherein the total weight of cannabinoids is at least 80% and said formulation further comprises at least 15% by weight remainder. 
     
     
         33 . The therapeutic formulation of  claim 31 , wherein the cannabis extract provides at least 30% THC by weight, and at least 30% CBD by weight. 
     
     
         34 . The therapeutic formulation of  claim 33  further comprising about 1-4% by weight added terpenoid compounds. 
     
     
         35 . The therapeutic formulation of  claim 34 , wherein the added terpenoid compounds consist essentially of about 0.05%-1% linalool by weight, about 0.05%-1% α-pinene by weight and about 0.05%-1% β-myrcene by weight. 
     
     
         36 . A therapeutic formulation comprising a cannabis component selected to provide about 24% THC by weight and about 48% CBD by weight 
     
     
         37 . The therapeutic formulation of  claim 36  further comprising at least 20% remainder by weight. 
     
     
         38 . A therapeutic formulation comprising: a cannabinoid component selected to provide about 60% THC by weight, about 20% CBD by weight, about 3% CBN by weight, about 3% Δ8-THC by weight, and about 4% CBG by weight. 
     
     
         39 . The therapeutic formulation of  claim 38  further comprising about 10% remainder by weight. 
     
     
         40 . The therapeutic formulation of  claim 38  further comprising about 1-4% by weight added terpenoid compounds. 
     
     
         41 . The therapeutic formulation of  claim 40 , wherein the added terpenoid compounds consist essentially of about 0.05%-1% linalool by weight, about 0.05%-1% α-pinene by weight and about 0.05%-1% β-myrcene by weight. 
     
     
         42 . A therapeutic formulation comprising a cannabinoid component selected to provide about 20% CBD by weight and about 60% CBN by weight. 
     
     
         43 . The therapeutic formulation of  claim 42  and at least 10% remainder by weight. 
     
     
         44 . The therapeutic formulation of  claim 42  further comprising:
 about 3% THC by weight, about 1% THCA by weight, about 1% A8-THC by weight, and about 4% CBG by weight; 
 added terpenoid compounds of 1%-4% by weight wherein the added terpenoid compounds consist essentially of about 2% limonene, about 9% linalool, about 6.5% α-pinene, about 2% α-terpineol, about 5% valencene, about 4.5% α-bisabolol, about 43% β-myrcene, about 13% β-caryophyllene, about 5% β-ocimene and about 8% α-humulene by weight; and 
 about 5% lecithin by volume.